A Study Evaluating the Pharmacokinetics of Ceftobiprole When Taken by Obese Patients
Status:
Completed
Trial end date:
2007-11-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to compare the pharmacokinetics (how drugs are
absorbed in the body, how they are distributed within the body and how they are removed from
the body over time) of ceftobiprole in morbidly obese patients and non-obese patients. The
secondary objectives are to assess the pharmacodynamics (the study of the action or effects a
drug has on the body) and to assess safety and tolerability of ceftobiprole in order to
support dosing recommendations in the morbidly obese population.
Phase:
Phase 1
Details
Lead Sponsor:
Basilea Pharmaceutica
Collaborator:
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.